PharVision Advisers’s Douglas Emmett DEI Stock Holding History

PharVision Advisers’s Portfolio DEI Stock Details DEI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,559	Closed	-$189K	–	689
2025 Q2	$189K	Buy	+12,559	New	+$181K	0.27%	212

Other funds holding DEI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

FPA

First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PharVision Advisers's DEI Position: Q3 2025 in Review

PharVision Advisers sold out of Douglas Emmett (DEI) in Q3 2025, closing a stake of 12,559 shares — an estimated $189K sold.

PharVision Advisers first reported a position in DEI in Q2 2025 and held it in 1 quarter. The position peaked at $189K in Q2 2025. 281 funds tracked by Wall St. Rank hold DEI as of Q3 2025.

PharVision Advisers reported no remaining Douglas Emmett position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 12,559 Douglas Emmett shares in Q3 2025, an estimated $189K.
PharVision Advisers first reported a position in Douglas Emmett in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Douglas Emmett position peaked at $189K in Q2 2025.
281 funds tracked by Wall St. Rank held Douglas Emmett as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.